PMID- 33133213
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2020
DP  - 2020
TI  - Ginsenoside Rg1 Alleviates Podocyte Injury Induced by Hyperlipidemia via 
      Targeting the mTOR/NF-kappaB/NLRP3 Axis.
PG  - 2735714
LID - 10.1155/2020/2735714 [doi]
LID - 2735714
AB  - BACKGROUND: Podocyte injury plays an important role in diabetic nephropathy (DN). 
      The aim of this study was to determine the potential therapeutic effects of the 
      ginsenoside Rg1 on hyperlipidemia-stressed podocytes and elucidate the underlying 
      mechanisms. METHODS: In vitro and in vivo models of DN were established as 
      previously described, and the expression levels of relevant markers were analyzed 
      by Western blotting, real-time Polymerase Chain Reaction (PCR), 
      immunofluorescence, and immunohistochemistry. RESULTS: Ginsenoside Rg1 alleviated 
      pyroptosis in podocytes cultured under hyperlipidemic conditions, as well as in 
      the renal tissues of diabetic rats, and downregulated the mammalian target of 
      rapamycin (mTOR)/NF-kappaB pathway. In addition, Rg1 also inhibited 
      hyperlipidemia-induced NLRP3 inflammasome in the podocytes, which was abrogated 
      by the mTOR activator L-leucine (LEU). The antipyroptotic effects of Rg1 
      manifested as improved renal function in the DN rats. CONCLUSION: Ginsenoside Rg1 
      protects podocytes from hyperlipidemia-induced damage by inhibiting pyroptosis 
      through the mTOR/NF-kappaB/NLRP3 axis, indicating a potential therapeutic function in 
      DN.
CI  - Copyright (c) 2020 Tao Wang et al.
FAU - Wang, Tao
AU  - Wang T
AUID- ORCID: 0000-0001-6924-0166
AD  - School of Traditional Chinese Medicine, Capital Medical University, 10 
      Youanmenwai, Xitoutiao, Fengtai District, Beijing, China.
AD  - School of North Sichuan Medical College, Nanchong 637000, China.
FAU - Gao, Yanbin
AU  - Gao Y
AUID- ORCID: 0000-0003-3635-1040
AD  - School of Traditional Chinese Medicine, Capital Medical University, 10 
      Youanmenwai, Xitoutiao, Fengtai District, Beijing, China.
AD  - Beijing Key Lab of TCM Collateral Disease Theory Research, 10 Youanmenwai, 
      Xitoutiao, Fengtai District, Beijing, China.
FAU - Yue, Rongchuan
AU  - Yue R
AUID- ORCID: 0000-0001-7969-935X
AD  - Department of Cardiology, Affiliated Hospital of North Sichuan Medical College, 
      Nanchong 637000, China.
FAU - Wang, Xiaolei
AU  - Wang X
AD  - School of Traditional Chinese Medicine, Capital Medical University, 10 
      Youanmenwai, Xitoutiao, Fengtai District, Beijing, China.
FAU - Shi, Yimin
AU  - Shi Y
AD  - School of Traditional Chinese Medicine, Capital Medical University, 10 
      Youanmenwai, Xitoutiao, Fengtai District, Beijing, China.
FAU - Xu, Jiayi
AU  - Xu J
AD  - School of Traditional Chinese Medicine, Capital Medical University, 10 
      Youanmenwai, Xitoutiao, Fengtai District, Beijing, China.
FAU - Wu, Bingjie
AU  - Wu B
AD  - School of Traditional Chinese Medicine, Capital Medical University, 10 
      Youanmenwai, Xitoutiao, Fengtai District, Beijing, China.
FAU - Li, Yimeng
AU  - Li Y
AD  - School of Traditional Chinese Medicine, Capital Medical University, 10 
      Youanmenwai, Xitoutiao, Fengtai District, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20201009
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7568787
COIS- The authors declare no conflicts of interest.
EDAT- 2020/11/03 06:00
MHDA- 2020/11/03 06:01
PMCR- 2020/10/09
CRDT- 2020/11/02 06:16
PHST- 2020/04/26 00:00 [received]
PHST- 2020/08/03 00:00 [revised]
PHST- 2020/09/27 00:00 [accepted]
PHST- 2020/11/02 06:16 [entrez]
PHST- 2020/11/03 06:00 [pubmed]
PHST- 2020/11/03 06:01 [medline]
PHST- 2020/10/09 00:00 [pmc-release]
AID - 10.1155/2020/2735714 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2020 Oct 9;2020:2735714. doi: 
      10.1155/2020/2735714. eCollection 2020.